Immunity claims are next on FTC’s radar, says legal expert

- Last updated on GMT

Related tags: Federal trade commission, Influenza, Ftc

Immunity is likely to be the next major focus for the US Federal Trade Commission (FTC) as it closes its fist over fraudulent dietary supplement products, suggests a food and drug lawyer.

The issue – which is already on the agency’s hit list – will most certainly be in the spotlight during the weeks ahead as the potential swine flu epidemic has already triggered the promotion of supplements purporting to protect against the virus, says Marc Ullman, partner at Ullman, Shapiro & Ullman.

“Any company that engages in that kind of marketing is inviting very swift and very serious enforcement action (…) I think FTC and FDA will be all over this,”​ he tells Lorraine Heller in this podcast.

Ingredient firms beware

In addition, Ullman predicts that a recent FTC clamp-down against a weight loss ingredient supplier could be heralding a change of tides.

“I suspect that this may the first in a series of cases that we see from FTC directed at ingredients suppliers.”

Related news

Show more

Related products

show more

ADULTERATION: MEASURES TO BE ON THE LOOKOUT FOR

ADULTERATION: MEASURES TO BE ON THE LOOKOUT FOR

SABINSA | 15-Apr-2020 | Technical / White Paper

Dramatic demand for herbal extracts is pressuring global raw material supply chains already fraught with COVID-19 challenges. The conditions have the potential...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars